Since Martin Cline’s initial attempts at modifying human DNA to cure thalassemia in 1980, a number of genetically modified therapies have been / are being investigated in clinical trials, across the world. Initially, genetically modified therapies were being developed for the treatment of rare genetic disorders; however, of late, such advanced therapies are also being developed for treating chronic disease indications, such as rheumatoid arthritis, Alzheimer’s disease and Parkinson’s disease.
Promising therapeutic outcomes demonstrated across several clinical studies of gene therapies and other genetically modified therapies, such as T-cell therapies, have captured the attention of many pharmaceutical companies and academic research institutes. The approval of Kymriah, a CAR-T cell therapy, in August 2017, further convinced industry players of the immense potential of such ATMPs. It is also worth noting that significant amount of capital has been invested by various stakeholders and venture capital firms to support the development and commercialization of this relatively new and upcoming generation of pharmacological interventions. In fact, in the first three quarters of 2020 (January – September), the pharmaceutical industry reportedly raised close to USD 16 billion (an increase of 18% as compared to the same period in 2019) for the development of gene based, cell based and other regenerative therapies. Furthermore, over 3,000 clinical studies have been initiated in this field since 1989. The aforementioned clinical evaluations highlight the rapid pace at which the development of gene therapies is taking place around the world.
Majority of the companies present in this domain, were established during the time period 2001-2005, followed by those founded during 2011-2015. It is important to highlight that there has been a gradual increase in the number of viral vector and gene therapy manufacturers being established over the last 3-4 decades. This has further led to an increase in the number of genetically modified therapies being developed across different stages.
Further, most of the players involved in this domain (56%) are contract service providers, of which, 23% players are mid-sized firms and more than 20% companies are large firms. Additionally, 14% players manufacture viral vectors and gene therapies for both in-house requirements and contract purposes. In fact, we identified 30% players that manufacture viral vectors and gene therapies solely for in-house purposes.
A detailed information on the key players, partnerships inked by the manufacturers, company competitiveness, capacity analysis, demand analysis and the likely market evolution, was done by Roots Analysis in Q1 2021. For Further, information visit this link: